A new potential game-changer in the fight against treatment-resistant ovarian cancer is gaining attention. Relacorilant, when teamed up with the chemotherapy drug nab-paclitaxel, has shown promising results in a phase 3 trial known as ROSELLA. The trial, organized by Corcept Therapeutics in California with help from The GOG Foundation, involved 381 patients across the globe, including countries like the U.S., Europe, and Australia.
This extensive study highlighted a notable 30% reduction in the risk of disease progression for patients with platinum-resistant ovarian cancer when treated with this combination, compared to just using nab-paclitaxel. In such cases, the cancer tends to return within six months after platinum-based therapy. Importantly, researchers observed a “significant improvement” in overall patient survival rates with these drugs.
Administered orally, Relacorilant was found to be “well-tolerated” by patients, without leading to any heightened side effects. The drug regimen involves taking Relacorilant the day before, the day of, and the day after receiving nab-paclitaxel, which is infused weekly. The study’s findings are expected to be shared at an upcoming medical conference, and results from an earlier phase were published in the Journal of Clinical Oncology this year.
Ovarian cancer, recognized by the Ovarian Cancer Research Alliance as the fifth leading cause of cancer-related deaths in women, remains the deadliest among gynecologic cancers. Dr. Alexander B. Olawaiye, a lead researcher in the ROSELLA trial, expressed the importance of this breakthrough. He explained to Fox News Digital that Relacorilant is innovative in its approach to tackling cancers with limited treatment options.
Dr. Olawaiye praised his research team for their relentless efforts and thanked the women who participated in the trial. He emphasized the significance of having potentially another effective treatment option available. With a 30% reduction in the risk of death observed among trial participants, the findings are indeed promising.
Dr. Brian Slomovitz from Mount Sinai Medical Center in Miami Beach also weighed in on the results. He acknowledged the tough battle against ovarian cancer, particularly when the disease resists standard treatments. According to Slomovitz, most past trials have unfortunately been unsuccessful, but the ROSELLA trial presents a beacon of hope.
He viewed this trial as a promising opportunity to utilize a unique drug that has delivered “positive, encouraging results.” The 30% decrease in recurrence and death risk presents a “refreshing” development, offering new hope to patients. Dr. Olawaiye is optimistic about the treatment receiving clinical approval soon.
As research continues to evolve, the field of cancer treatment has seen numerous advances in recent years. The introduction of Relacorilant is yet another step forward in improving therapeutic options for those battling ovarian cancer.
